Therapeutic Effect Of The Root Of Mallotus Apelta (Lour.) Muelle.-Arg. On Duck Hepatitis B Virus

Background: Hepatitis B virus (HBV) infection is a major global public health problem. Of the approximately 2 billion people who have been infected worldwide, more than 350 million are chronic carriers of HBV. Approximately 15-40% of infected patients will develop cirrhosis, liver failure, or hepatocellular carcinoma (HCC). HBV infection accounts for 500 000 to 1.2 million deaths each year and is the 10th leading cause of death worldwide. Hepatocellular carcinoma incidence has increased worldwide, and the disease is now the 5th most frequent cancer, killing 300 000-500 000 people each year. Currently, two kind of drugs are widely approved globally (Europe, North America and Asia) for treatment of Chronic Hepatitis B (CHB) : conventional interferon Alfa (IFNa) and nucleoside analogue such as lamivudine. Conventional IFNa, with its dual immunomodulatory and antiviral effects, is an option for the treatment of CHB. Patients who are sustained responders to conventional IFNa have an improved disease outcome and complication-free survival. However, conventional IFNa has a modest efficacy rate, is associated with undesirable side effects, and three-times-weekly dosing by injection is an inconvenient regimen for patients. Lamivudine offers the advantages of minimal side effects and ease of administration. Its major disadvantages are its modest efficacy rate,...